- Home
- CGEN vs JHI Comparison
CGEN vs JHI Comparison
Compare CGEN & JHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- JHI
- Stock Information
- Founded
- CGEN 1993
- JHI 1971
- Country
- CGEN Israel
- JHI United States
- Employees
- CGEN N/A
- JHI N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- JHI Trusts Except Educational Religious and Charitable
- Sector
- CGEN Health Care
- JHI Finance
- Exchange
- CGEN Nasdaq
- JHI Nasdaq
- Market Cap
- CGEN 142.8M
- JHI 124.3M
- IPO Year
- CGEN 2000
- JHI N/A
- Fundamental
- Price
- CGEN $1.60
- JHI $13.87
- Analyst Decision
- CGEN Strong Buy
- JHI
- Analyst Count
- CGEN 2
- JHI 0
- Target Price
- CGEN $4.00
- JHI N/A
- AVG Volume (30 Days)
- CGEN 445.1K
- JHI 29.5K
- Earning Date
- CGEN 11-12-2024
- JHI 01-01-0001
- Dividend Yield
- CGEN N/A
- JHI 6.80%
- EPS Growth
- CGEN N/A
- JHI N/A
- EPS
- CGEN 0.02
- JHI 1.05
- Revenue
- CGEN $59,852,000.00
- JHI N/A
- Revenue This Year
- CGEN $57.27
- JHI N/A
- Revenue Next Year
- CGEN N/A
- JHI N/A
- P/E Ratio
- CGEN $88.75
- JHI $12.47
- Revenue Growth
- CGEN 698.03
- JHI N/A
- 52 Week Low
- CGEN $1.35
- JHI $11.63
- 52 Week High
- CGEN $3.03
- JHI $13.40
- Technical
- Relative Strength Index (RSI)
- CGEN 51.01
- JHI 33.37
- Support Level
- CGEN $1.55
- JHI $13.84
- Resistance Level
- CGEN $1.68
- JHI $14.45
- Average True Range (ATR)
- CGEN 0.08
- JHI 0.08
- MACD
- CGEN 0.01
- JHI -0.06
- Stochastic Oscillator
- CGEN 52.17
- JHI 11.48
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.